Literature DB >> 30178865

L-butyl phthalein improves neural function of vascular dementia mice by regulating the PI3K/AKT signaling pathway.

D-P Chen1, S-H Hou, Y-G Chen, M-S Chen, Z-Z Hu, Z-J Zhang.   

Abstract

OBJECTIVE: L-3-n-butylphthalide (L-NBP) is a type of anti-ischemic cranial nerve protective drug that may act on vascular dementia (VD). Phosphatidylinositol-3 kinase (PI3K)/protein kinase B (AKT/PKB) signaling pathway can up-regulate B-cell lymphoma 2 (Bcl-2) expression, reduce reactive oxygen species (ROS) production, and alleviate cell apoptosis. This study aimed at investigating the role of L-NBP on neurological function and cell apoptosis in VD mouse through regulating PI3K/AKT signaling pathway.
MATERIALS AND METHODS: The mice were divided into four groups, including Sham, VD, VD + solvent, and VD + L-NBP. HT22 cells were cultured in vitro and treated by ischemia/reperfusion (I/R). HT22 cells were divided into four groups, including I/R, VD + solvent, VD + L-NBP, and VD + L-NBP + LY294002 groups. Phosphorylated AKT (p-AKT) and Bcl-2 expressions were tested. ROS content in hippocampus tissue was detected by flow cytometry. Cell apoptosis was evaluated by transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) assay.
RESULTS: ROS content and cell apoptosis increased, while p-AKT and Bcl-2 expressions reduced in hippocampus tissue from VD group compared with sham group. L-NBP significantly up-regulated p-AKT and Bcl-2 expressions and decreased ROS content and cell apoptosis in hippocampus tissue. I/R treatment markedly induced HT22 cell apoptosis and ROS production, and reduced p-AKT and Bcl-2 expressions. L-NBP treatment markedly up-regulated p-AKT and Bcl-2 levels, restrained cell apoptosis, and reduced ROS content in TH22 cells intervened by I/R. LY294002 apparently attenuated the protective effect of L-NBP on HT22 cells.
CONCLUSIONS: L-NBP protects VD by up-regulating PI3K/AKT signaling pathway, elevating Bcl-2 expression, reducing nerve cell apoptosis, and restraining ROS production.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30178865     DOI: 10.26355/eurrev_201808_15740

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  4 in total

1.  L-3-n-butylphthalide soft capsules in the treatment of Parkinson disease dementia: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Rui Zhong; Qingling Chen; Xinyue Zhang; Mengmeng Li; Weihong Lin
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

Review 2.  Role of Butylphthalide in Immunity and Inflammation: Butylphthalide May Be a Potential Therapy for Anti-Inflammation and Immunoregulation.

Authors:  Yiliu Zhang; Yijun Ren; Xiqian Chen; Shuwen Deng; Wei Lu
Journal:  Oxid Med Cell Longev       Date:  2022-04-05       Impact factor: 6.543

Review 3.  Efficacy and safety of 3-n-butylphthalide for the treatment of cognitive impairment: A systematic review and meta-analysis.

Authors:  Qiulu Zhou; Chao Han; Yun Xia; Fang Wan; Sijia Yin; Yunna Li; Liang Kou; Xiaosa Chi; Junjie Hu; Yadi Sun; Jiawei Wu; Wenkai Zou; Jinsha Huang; Tao Wang
Journal:  CNS Neurosci Ther       Date:  2022-09-01       Impact factor: 7.035

4.  RNA sequencing-based identification of the regulatory mechanism of microRNAs, transcription factors, and corresponding target genes involved in vascular dementia.

Authors:  Kaiyue Zhao; Li Zeng; Zhongdi Cai; Mimin Liu; Ting Sun; Zhuorong Li; Rui Liu
Journal:  Front Neurosci       Date:  2022-09-20       Impact factor: 5.152

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.